

**VALUATION REPORT**  
on  
**Fair Value of Equity Shares**

**Vadivarhe Speciality Chemicals Limited**

**Valuation Date / Relevant Date – 10<sup>th</sup> March 2026**

**Report Date – 13<sup>th</sup> March 2026**

Bhavesh M Rathod  
Chartered Accountants, Registered Valuer – SFA  
Office Add: Office No. 515, 5th Floor, Dimple Arcade, Behind Sai Dham Temple,  
Thakur Complex, Kandivali East, Mumbai, Maharashtra - 400101  
Registered Add: 12D, White Spring, A wing, Rivali Park Complex,  
Western Express Highway, Borivali East, Mumbai 400066  
Email: [bhavesh@cabr.in](mailto:bhavesh@cabr.in)  
Mobile: +91 9769 11 34 90

## Table of Contents

1	Context and Purpose.....	3
2	Conditions and major assumptions.....	3
3	Background of the Company.....	5
4	Valuation Premise .....	6
5	Valuation Date.....	6
6	Declaration of Independence of valuer and Financial Interest.....	6
7	Valuation Standards .....	6
8	Valuation Methodology and Approach.....	6
9	Source of Information .....	9
10	Caveats .....	10
11	Distribution of Report .....	11
12	Opinion on Fair Value of Equity Shares.....	11
13	Annexure 1 .....	13

## Valuation Analysis

We refer to our Engagement Letter as independent valuers of **Vadivarhe Speciality Chemicals Limited** (the “Company”). In the following paragraphs, we have summarized our valuation Analysis (the “Analysis”) of the business of the Company as informed by the management and detailed herein, together with the description of the methodologies used and limitation on our scope of work.

### 1 Context and Purpose

Based on discussion with the management, we understand that the Company is evaluating the possibility of **Fair Value of Equity shares under the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018**. In the context of the proposed transaction, the management requires our assistance in determining the **Fair Value of Equity shares** of the Company.

#### Proposed Transaction:

During the Financial Year 2025-26, Company is evaluating the possibility of issuing further securities to prospective investors. In this context, the management of **Vadivarhe Speciality Chemicals Limited** (the “Management”) has requested us to estimate the fair value of the Equity Shares. - “Proposed Transaction”.

### 2 Conditions and major assumptions

#### Conditions

The historical financial information about the Company presented in this report is included solely for the purpose to arrive at value conclusion presented in this report and it should not be used by anyone to obtain credit or for any other unintended purpose. Because of the limited purpose as mentioned in the report, it may be incomplete and may contain departures from generally accepted accounting principles prevailing in the country. We have not audited, reviewed or compiled the financial statements and express no assurance on them.

Readers of this report should be aware that a business valuation is based on future earnings potential that may or may not be materialised.

This report is only to be used in its entirety, and for the purpose stated in the report. No third parties should rely on the information or data contained in this report without the advice of their lawyer, attorney or accountant.

We acknowledge that we have no present or contemplated financial interest in the Company. Our fees for this valuation are based upon our normal billing rates, and not contingent upon the results or the value of the business or in any other manner. We have no responsibility to modify this report for events and circumstances occurring subsequent to the date of this report.

We have, however, used conceptually sound and generally accepted methods, principles and procedures of valuation in determining the value estimate included in this report. The valuation analyst, by reason of performing this valuation and preparing this report, is not to require to give expert testimony nor to be in attendance in court or at any government hearing with reference to the matters contained herein, unless prior arrangements have been made with the analyst regarding such additional engagement.

#### **Assumptions**

The opinion of value given in this report is based on information provided by the management of the Company and other sources as listed in the report. This information is assumed to be accurate and complete.

We have relied upon the representations contained in the public and other documents in our possession and any other assets or liabilities except as specifically stated to the contrary in this report.

We have not attempted to confirm whether or not all assets of the business are free and clear of liens and encumbrances, or that the owner has good title to all the assets.

We have also assumed that the business will be operated prudently and that there are no unforeseen adverse changes in the economic conditions affecting the business, the market, or the industry. This report presumes that the management of the Company will maintain the character and integrity of the Company.

We have been informed by the management that there are no significant lawsuits or any other undisclosed contingent liabilities which may potentially affect the business, except as may be disclosed elsewhere in this report. We have assumed that no costs or expenses will be incurred in connection with such liabilities, except as explicitly stated in this report.

### 3 Background of the Company

Vadivarhe Speciality Chemicals Limited, incorporated on 23<sup>rd</sup> February 2009 is a globally active Indian chemical producer, focused on organic chemicals and custom synthesis. The company is primarily engaged in the manufacturing, marketing & supply of:

- Speciality chemicals
- Active Pharmaceutical Ingredients (APIs)
- Bio Chemicals
- Organic Chemicals
- Inorganic Chemicals
- Drug Intermediates
- Personal care ingredients
- Bulk Drugs

Company URL: - <https://www.vscl.in>

Further data of the company is as under:

CIN	L24100MH2009PLC190516
Company Name	VADIVARHE SPECIALITY CHEMICALS LIMITED
ROC Name	ROC Mumbai II
Registration Number	190516
Date of Incorporation	23/02/2009
Email Id	<a href="mailto:accounts@vscl.co.in">accounts@vscl.co.in</a>
Registered Address	GAT NO. 204, VADIVARHE, IGATPURI, Maharashtra, India, 422403
Address at which the books of account are to be maintained	-
Listed in Stock Exchange(s) (Y/N)	Yes
Category of Company	Company limited by shares
Subcategory of the Company	Non-government company
Class of Company	Public
ACTIVE compliance	ACTIVE Compliant
Authorised Capital (Rs)	15,00,00,000
Paid up Capital (Rs)	12,78,27,500
Date of last AGM	29/09/2025
Date of Balance Sheet	31/03/2025
Company Status	Active

Directors and Key Managerial Persons:

DIN/PAN	Name	Designation	Date of Appointment
00834085	Meena Sunil Pophale	Whole-time director	23/02/2009
06816384	Ravindra Keshav Paranjpe	Director	02/05/2017
02795136	Prasanna Prabhakar Rege	Director	02/05/2017
07805920	Uttara Adwait Kher	Director	02/05/2017
00064412	Sunil Haripant Pophale	Director	23/02/2009
*****9334J	Madhukar Sitaram Suvarna	CFO	26/08/2025
*****7849P	Manoj Kumar	Company Secretary	27/05/2024

**Shareholding Details as on the date of report**

Particulars	No. of Shares	% Holding
<b>Promoter &amp; Promoter Group</b>		
Meena Sunil Pophale	60,38,000	47.24%
Aditi Sunil Pophale	15,00,000	11.73%
Sunita Ajay Ramnathkar	3,000	0.02%
Sunil Haripant Pophale	10,01,000	7.83%
Manasi Sunil Pophale	250	0.00%
<b>Public</b>	42,40,500	33.17%
<b>Total</b>	<b>1,27,82,750</b>	<b>100.00%</b>

Face Value Per Share is Rs. 10.00/-

#### 4 Valuation Premise

The premise of value for our analyses is going concern value as there is neither a planned or contemplated discontinuance of any line of business nor any liquidation of the Company.

#### 5 Valuation Date

The Analysis of the Fair Value of Equity Shares of **Vadivarhe Speciality Chemicals Limited** as on **10<sup>th</sup> March 2026** based on the Financials as on **30<sup>th</sup> September 2025**.

#### 6 Declaration of Independence of valuer and Financial Interest

I hereby declare that I am independent of the subject firms for valuation and have not been under any direct or indirect influence, which may affect the valuation exercise. I also state that I have no financial interest in the subject company for Valuation.

#### 7 Valuation Standards

The Report has been prepared in compliance with the internationally accepted valuation standards and valuation standard adopted by ICAI Registered Valuers Organisation.

#### 8 Valuation Methodology and Approach

The standard of value used in the Analysis is "Fair Value", which is often defined as the price, in terms of cash or equivalent, that a buyer could reasonably be expected to pay, and a seller could reasonably be expected to accept, if the business were exposed for sale on the open market for a reasonable period of time, with both buyer and seller being in possession of the pertinent facts and neither being under any compulsion to act.

Valuation of a business is not an exact science and ultimately depends upon what it is worth to a serious investor or buyer who may be prepared to pay a substantial goodwill. This exercise may be carried out using various methodologies, the relative emphasis of each often varying with:

- whether the entity is listed on a stock exchange

- industry to which the Company belongs.
- past track record of the business and the ease with which the growth rate in cash flows to perpetuity can be estimated.
- Extent to which industry and comparable Company information is available.

The results of this exercise could vary significantly depending upon the basis used, the specific circumstances and professional judgment of the valuer. In respect of going concerns, certain valuation techniques have evolved over time and are commonly in vogue. These can be broadly categorised as follows:

### **1. Asset Approach**

#### **Net Asset Value Method ("NAV")**

The value arrived at under this approach is based on the audited financial statements of the business and may be defined as Shareholders' Funds or Net Assets owned by the business. The balance sheet values are adjusted for any contingent liabilities that are likely to materialise.

The Net Asset Value is generally used as the minimum break-up value for the transaction since this methodology ignores the future return the assets can produce and is calculated using historical accounting data that does not reflect how much the business is worth to someone who may buy it as a going concern.

### **2. Market Approach**

#### **Comparable Company Market Multiple Method**

Under this methodology, market multiples of comparable listed companies are computed and applied to the business being valued in order to arrive at a multiple based valuation. The difficulty here in the selection of a comparable company since it is rare to find two or more companies with the same product portfolio, size, capital structure, business strategy, profitability and accounting practices.

Whereas no publicly traded company provides an identical match to the operations of a given company, important information can be drawn from the way comparable enterprises are valued by public markets. In case of early stage company and different business model the problem aggravates further.

#### **Comparable Transactions Multiple Method**

This approach is somewhat similar to the market multiples approach except that the sales and EBITDA multiples of reported transactions in the same industry in the recent past are applied to the sales and EBITDA of the business being valued.

### **3. Income Approach**

#### **Discounted Cash Flows - "DCF"**

DCF uses the future free cash flows of the company discounted by the firm's weighted average cost of capital (the average cost of all the capital used in the business, including debt and equity), plus a risk factor measured by beta, to arrive at the present value.

Beta is an adjustment that uses historic stock market data to measure the sensitivity of the Company's cash flow to market indices, for example, through business cycles.

The DCF method is a strong valuation tool, as it concentrates on cash generation potential of a business. This valuation method is based on the capability of a company to generate cash flows in the future. The free cash flows are projected for a certain number of years and then discounted at a discount rate that reflects a Company's cost of capital and the risk associated with the cash flows it generates. DCF analysis is based mainly on the following elements:

- Projection of financial statements (key value driving factors)
- The cost of capital to discount the projected cash flows.



#### **Profit Earning Capacity Value (PECV) Method**

This method of valuation presumes the continuity of business and uses the past and projected earnings to arrive at an estimate of future maintainable profits. For the purpose of the Profit Earning Capacity Value (PECV) of the shares, the commonly accepted approach is to capitalize average earnings, past and projected at an appropriate rate of capitalization, to arrive at a fair value per share. In the calculation of PECV, provision for taxation at the current statutory rate is normally considered because the crux of estimate the PECV lies in the assessment of the future maintainable profits of the business. It should not be overlooked that the valuation is for the future and that it is the future maintainable streams of earnings that is of greater significance in the process of valuation.

#### **Valuation Methodology**

The application of any particular method of valuation depends on the purpose for which the valuation is done. Although different values may exist for different purposes, it cannot be too strongly emphasized that a valuer can only arrive at one value for one purpose.

In this case, the Company being a listed Company, we have considered valuation regulations applicable to preferential issue of Equity Shares as defined in Securities and Exchange Board of India (Issue of Capital & Disclosure) Regulations, 2018, the requirements of the Articles of Association of the Company and the provisions of the Companies (Share Capital and Debentures) Rules, 2014 (as amended).

**SEBI Regulations for requirement of Valuation:**

#### **SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED**

The relevant Regulations under SEBI (ICDR) are reproduced as under:

**Regulation 165.** Where the shares of an issuer are not frequently traded, the price determined by the issuer shall take into account the valuation parameters including book value, comparable trading multiples, and such other parameters as are customary for valuation of shares of such companies:

Provided that the issuer shall submit a certificate stating that the issuer is in compliance of this regulation, obtained from an independent valuer to the stock exchange where the equity shares of the issuer are listed.

**Regulation 161:** "relevant date" means: a) in case of preferential issue of equity shares, the date thirty days prior to the date on which the meeting of shareholders is held to consider the proposed preferential issue:

*Explanation:* Where the relevant date falls on a weekend or a holiday, the day preceding the weekend, or the holiday will be reckoned to be the relevant date.

**Regulation 166A (1): Other conditions for pricing**

Any preferential issue, which may result in a change in control or allotment of more than five per cent. of the post issue fully diluted share capital of the issuer, to an allottee or to allottees acting in concert, shall require a valuation report from an independent registered valuer and consider the same for determining the price:

Provided that the floor price, in such cases, shall be higher of the floor price determined under sub-regulation (1), (2) or (4) of regulation 164, as the case may be, or the price determined under the valuation report from the independent registered valuer or the price determined in accordance with the provisions of the Articles of Association of the issuer, if applicable.

Provided further that if any proposed preferential issue is likely to result in a change in control of the issuer, the valuation report from the registered valuer shall also cover guidance on control premium, which shall be computed over and above the price determined in terms of the first proviso.

In the instant case, the shares are listed on the National Stock Exchange but are infrequently traded. The traded turnover on the Exchange during the 240 trading days in the relevant period is shown in the table below.

Number of Equity Shares traded. (A)	Total no. of Equity Shares of the Target Company during the Relevant Period (B)	Trading Turnover (as a % of Total Equity Shares listed during the Relevant Period) (A/B)
<b>NSE Limited (NSE)</b>		
6,18,000	1,27,82,750	4.83%

Our choice of methodology and valuation has been arrived using usual and conventional methodologies adopted for purposes of a similar nature and our reasonable judgment, in an independent and bona fide manner based on our previous experience of assignments of similar nature.

## 9 Source of Information

The Analysis is based on trading prices and volumes as available in the public domain. Specifically, the sources of information include:

- Historical Data of Trading Price and Volume traded of the stock on National Stock Exchange

Further, we have also been informed by the Company that.

1. The Equity Shares of the Company are listed on the National Stock Exchange.
2. The Equity Shares are infrequently traded on the National Stock Exchange and does not meet the definition of Frequently traded shares as per Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended.
3. The Company is proposing to hold Annual General Meeting of Members on 09<sup>th</sup> April 2026 to approve the proposed preferential issue and hence, the relevant date is 10<sup>th</sup> March 2026.
4. The present issue of Equity Shares shall not result in change in control of the Company.
5. Management certified projected financial statements for period of 5 years for the year ending FY26 to FY30.
6. Details of Shareholding and numbers of Equity Shares as on valuation date.

In addition to the above, we have also obtained such other information and explanations from the Company as were considered relevant for the purpose of the valuation. It may be mentioned that the Management has been provided the opportunity to review our draft report as part of our standard practice to make sure that factual inaccuracies are avoided in our final report.

## 10 Caveats

Provision of valuation recommendations and considerations of the issues described herein are areas of our regular corporate advisory practice. The services do not represent accounting, assurance, financial due diligence review, consulting, transfer pricing or domestic/international tax-related services that may otherwise be provided by us.

We have relied on data from Recognized Stock Exchange. This source is considered to be reliable and therefore, we assume no liability for the accuracy of the data.

The valuation worksheets prepared for the exercise are proprietary to the Valuer and cannot be shared. Any clarifications on the workings will be provided on request, prior to finalizing the Report, as per the terms of our engagement.

The scope of our work has been limited both in terms of the areas of the business and operations which we have reviewed and the extent to which we have reviewed them.

The Valuation Analysis contained herein represents the value only on the date that is specifically Stated in this Report.

We have no present or planned future interest in the Company and the fee for this Report is not contingent upon the values reported herein.

Our Valuation analysis should not be construed as investment advice; specifically, we do not express any opinion on the suitability or otherwise of entering into any transaction with the Company.

Our Report is not nor should it be construed as our opining or certifying the compliance with the provisions of any law / standards including company, foreign exchange regulatory, accounting and taxation (including transfer pricing) laws / standards or as regards any legal, accounting or taxation implications or issues.

Our Report and the opinion / valuation analysis contained herein is not nor should it be construed as advice relating to investing in, purchasing, selling or otherwise dealing in securities. This report does

not in any manner address, opine on or recommend the prices at which the securities of the Company could or should transact.

## 11 Distribution of Report

The Analysis is confidential and has been prepared exclusively for **Vadivarhe Speciality Chemicals Limited**. It should not be used, reproduced or circulated to any other person or for any purpose other than as mentioned above, in whole or in part, without the prior written consent of the valuer. Such consent will only be given after full consideration of the circumstances at the time. However, we do understand that the report will be shared according to the terms of SEBI ICDR Regulation, 2018.

## 12 Opinion on Fair Value of Equity Shares

Based on our valuation exercise Fair Value of the Equity Shares as on 10<sup>th</sup> March 2026 is as under:

Method	In INR
Price determined by the independent registered valuer	19.19

Method	Value per share (*)	Weight	Product
Asset Approach	-5.19	0%	0.00
Market Approach	14.65	35.00%	5.13
Income Approach	21.63	65.00%	14.06
<b>Weight Average Value per share</b>			<b>19.19</b>

(\*) Refer Annexure for Working

Approach	Method	Selection	Rationale for selection
Asset Approach	NAV Method	-	The value as per the Net Asset Method is negative and shall not capture the future cashflow of the company. It serves as a valuation floor since most companies have a greater value as a going concern than they would if they were liquidated. Considering this, no weightage is considered for asset approach in the current valuation exercise.
Income Approach	DCF Method	Selected	The DCF method is considered as the most scientific method as it considers the time value of money, and the cash outflows required for increased levels of business forecast. It is considered relevant and appropriate in the case of companies which are in the growth phase of the business cycle, as in the present case. Accordingly, 65% weightage is considered for Income Approach for current valuation exercise
Market Approach	CCM Method	Selected	The CCM model typically provides a range of values for a company, derived from the valuations of its comparable peers. As this method offers a spectrum of values rather than a single point estimate, we have adopted the CCM method for a comprehensive assessment of a company's market position and its potential valuation. Accordingly, 35% weightage is considered for Market Approach for current valuation exercise.

	Market Price	-	The equity shares of the company are infrequently traded, and therefore the quoted market price does not represent a reliable indicator of the fair value of the shares. Accordingly, the market price method has not been considered for valuation.
--	--------------	---	--

**Control Premium**

The present issue of Equity Shares shall not result in change in control of the Company. Hence guidance on control premium is not considered under Regulation 166A.

We trust the above meets your requirements. Please feel free to contact us in case you require any additional information or clarifications.

Yours faithfully



Bhavesh M Rathod  
Chartered Accountants  
M No: 119158  
Registered Valuer - Securities or Financial Assets  
(Reg No: IBBI/RV/06/2019/10708)

Date: 13<sup>th</sup> March 2026  
Place: Mumbai

UDIN: **26119158YIXUH68276**

## 13 Annexure 1

### i. Asset Approach - Net Asset Value Method (NAV Method) as on 30<sup>th</sup> September 2025

		(INR Lakhs)
Particulars		Amount
<b>Assets</b>		
<b>Non-current assets</b>		
<b>Fixed Assets</b>		
-Tangible Assets		2,154.87
-CWIP		11.03
Long-term loans and advances		2.45
Non-Current Investment		5.00
Other Non-Current Assets		26.83
<b>Current assets</b>		
Inventories		1,086.09
Trade receivables		393.66
Cash and bank balances		57.75
Short-term loans and advances		134.84
Other Current Assets		2.81
<b>Total Assets</b>	<b>A</b>	<b>3,875.33</b>
<b>Liabilities</b>		
<b>Non-Current Liabilities</b>		
Long Term Borrowings		2,009.70
Long-Term Provisions		41.77
<b>Current liabilities</b>		
Short Term Borrowings		1,126.99
Trade payables		827.31
Other current liabilities		391.05
Short-Term Provisions		141.37
<b>Total Liabilities</b>	<b>B</b>	<b>4,538.19</b>
<b>Net-Worth</b>	<b>(A - B)</b>	<b>-662.86</b>
<b>No. of Shares</b>	<b>C</b>	<b>1,27,82,750</b>
<b>Value Per Share (in INR)</b>	<b>(A - B) / C</b>	<b>-5.19</b>

**ii. Market Approach - Comparable Companies Multiple Method (CCM Method)**

Particulars	P/ Sales
<b>Adjusted Average Peer Ratio (Note 1)</b>	<b>0.46</b>
Sales of Company (in INR Lakhs) (TTM)	4,048.09
<b>Equity Value (in INR Lakhs)</b>	<b>1,872.24</b>
No. of Shares	1,27,82,750
<b>Value per share (in INR)</b>	<b>14.65</b>

**Note 1: -**

**P/ Sales Multiple of Listed Peer Company**

Particulars	P/ Sales	Source
Alkali Metals Ltd	0.71	
Crestchem Ltd	0.95	<a href="https://www.screener.in/">https://www.screener.in/</a>
Sanginita Chemicals Ltd	0.19	
<b>Average Ratio</b>	<b>0.62</b>	
Less: Size Discount (*)	@25%	-0.15
<b>Adjusted Average Ratio</b>	<b>0.46</b>	

(\*) Size Discount of 25% has been applied to account for the differences in scale and operational capacities between the target company and the listed comparable companies.

**iii. Income Approach - Discounted Cash Flows (DCF Method)**

We have been provided with the business projection of the Company for **Five years** by the Management, which we have considered for our Analysis. Accordingly, the projected free cash flows to Equity ("FCFE") based on these financial statements is set out below:

(INR Lakhs)

Number of Months	6	12	12	12	12	
Particulars	FY26	FY27	FY28	FY29	FY30	TV
<b>PAT</b>	150.00	-143.57	134.29	538.82	955.80	729.55
<b>Add: Depreciation</b>	172.87	342.30	313.46	288.94	268.10	268.10
<b>Less: Capex</b>	-138.97	-150.00	-150.00	-150.00	-150.00	
<b>(Increase)/ decrease in working capital</b>	-264.39	-62.79	-99.13	-148.15	-222.37	-268.10
<b>Free cash flow to firm ('FCFF')</b>	-80.50	-14.06	198.62	529.60	851.53	729.55
<b>Net Debt Taken / (Repaid)</b>	38.55	13.55	-8.35	-26.98	-42.28	
<b>Other Non-Current Assets</b>	-6.71	-8.38	-10.48	-13.10	-16.38	
<b>Free cash flow to Equity ('FCFE')</b>	-48.66	-8.89	179.78	489.52	792.87	729.55

Annual factor		0.50	1.00	1.00	1.00	1.00
Discounting period (end year)		0.50	1.50	2.50	3.50	4.50
PV factor	18.79%	0.92	0.77	0.65	0.55	0.46
PV of FCFE		-44.65	-6.87	116.93	268.04	365.48

PV of FCFE for the horizon period	698.92	A
FCFE for terminal year	729.55	
WACC	18.79%	
Perpetuity Growth	2.00%	
Capitalisation Rate	16.79%	
Gross terminal value	4,346.18	
PV factor	0.46	
PV of terminal value	2,003.39	B
Enterprise value	2,702.31	A+B
Add: Fair Value of Investments (*)	5.00	
Add: Cash & Bank	57.75	
Fair Value of Equity	2,765.06	
No of Share	1,27,82,750	
Value Per Share (in INR)	21.63	

(\*) Refer Note 2 for Fair Value

#### Assumptions

Cost of Equity	18.79 %
Long Term Growth Rate	2.00 %

#### Note 2: - Fair Value of Investment

(INR Lakhs)

Particulars	Book Value	Fair Value (*)
Equity Shares of NKGSB Co-Op Bank Ltd	5.00	5.00
<b>Total</b>	<b>5.00</b>	<b>5.00</b>

(\*) Book Value is considered as Fair Value

#### Terminal Value

The terminal value refers to the present value of the business as a going concern beyond the period of projections up to infinity. This value is estimated by taking into account expected growth rates of the business in future, sustainable capital investments required for the business as well as the estimates growth rate of the industry and economy. Based on dynamics of the sector and discussions with the Management we have assumed a terminal growth rate of **2.00 %** for the Company beyond the projections periods. The cash flows of **Rs. 729.55 Lakhs** have been used to determine the terminal value. Based on these assumptions the terminal value has been calculated at **Rs. 4,346.18 Lakhs**.

Using these cash flows and a discount rate of **18.79 %**, we estimate the equity value of the Company **Rs. 2,765.06 Lakhs.**

#### Discount Factor

Discount Factor considered for arriving at the present value of the free cash flows to the Equity Shares of the Company is the cost of equity. The cost of equity is computed using the capital asset pricing model (CAPM) using the formula shown below.

$$rE = rf + B (rM - rf) + CSP$$

Where,

rf = Risk free rate;

rM =Market return;

B = sensitivity of the index to the market / measure of market risk

CSP – Company Specific Risk

	Rate	Source
Risk free return (rf)	6.56 %	10-year average government bond yield from last 12 months
Market Return (Rm)	14.34 %	Return of BSE 500 from Feb 01, 1999, to September 30, 2025
Measure of market risk(B)	0.80	As the beta of the company is Negative, Beta is derived from the average beta of listed peer companies.
Company Specific Risk	6.00 %	Contingency of revenues, projected high profitability, achievability of projections

Based on the above parameters, the cost of Equity has been calculated at **18.79 %**.